OR WAIT 15 SECS
Melanie Sena is community editor of Pharmaceutical Technology.
GE Healthcare and Promosome sign a licensing agreement that gives GE Healthcare exclusive rights to a new suite of mammalian cell line development technologies.
GE Healthcare and Promosome LLC, a synthetic biology company, have signed a licensing agreement, giving GE Healthcare exclusive rights to a new suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
In-licensing of Promosome’s cell line development technologies will enable GE Healthcare to expand its offering with a cell-line generation service focused on delivering increased expression levels for hard-to-manufacture therapeutic proteins and improving manufacturing efficiency through increased protein yields.
GE Healthcare recently acquired Thermo Fisher’s HyClone cell culture media and sera business.
Source: GE Healthcare
Related Content:Industry News